1/1
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Version 2 2021-03-01, 17:01
Version 1 2021-02-11, 11:37
figure
posted on 2021-03-01, 17:01 authored by Adis journals on behalf of, Teresa Coelho, Yukio Ando, Merrill D. Benson, John L. Berk, Márcia Waddington Cruz, Peter J. Dyck, Julian D. Gillmore, Sami L. Khella, William J. Litchy, Laura Obici, Shiangtung W. Jung, Louis St. L. O’Dea, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Brett P. Monia, Morie GertzArticle full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
